Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Invex Therapeutics Ltd. ( (AU:IXC) ) just unveiled an announcement.
Invex Therapeutics Ltd announced the resignation of its Chairman, Mr. David McAuliffe, Executive Director, Dr. Thomas Duthy, and Company Secretary and CFO, Ms. Narelle Warren, with immediate effect. These resignations led to the cancellation of a requisitioned general meeting that was initially scheduled to address the removal of these directors. This development may impact the company’s governance and strategic direction, as well as its relationship with stakeholders, particularly the requisitioning shareholder, Celtic Capital Pte Ltd.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company specializing in the repurposing of the drug Exenatide for the treatment of neurological conditions associated with raised intracranial pressure. The company has trademarked this repurposed drug as Presendin™.
Average Trading Volume: 66,235
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$8.64M
See more insights into IXC stock on TipRanks’ Stock Analysis page.